MetaCap

Jaguar Health (JAGX) vs Skye Bioscience (SKYE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Skye Bioscience is the larger company by market cap ($3.1 million vs $3.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JAGX-95.46%SKYE-57.58%
+7%-47%-100%
Oct 7, 20261 yearNov 20, 2026
JAGX-95.26%SKYE-58.58%
+5%-48%-100%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JAGX versus SKYE key metrics
MetricJAGXSKYE
Share price$0.227$0.70
Market cap$3.03M$3.10M
1-day change-30.58%-11.03%
EPS (TTM)$-257.15$-7.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$11.51M—
Revenue growth (YoY)-1.52%—
Net income (latest FY)$-53.58M$-55.92M
Gross margin67.21%—
Operating margin-398.82%—
Net margin-465.42%—
52-week high$981.75$11.04
52-week low$0.22$0.484
Distance from 52-week high-99.98%-93.66%
Analyst consensus—none
Avg. price target upside—+9614.29%
Average volume2.40M88.19K
Shares outstanding13.35M4.42M
Employees472
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Jaguar Health

JAGX stock →

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

About Skye Bioscience

SKYE stock →

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

JAGX vs SKYE FAQ

Which is bigger, Jaguar Health or Skye Bioscience?

Skye Bioscience (SKYE) is larger, with a market capitalization of $3.10M compared with $3.03M for Jaguar Health (JAGX).

Are Jaguar Health and Skye Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons